Investors & Opportunities | Lebrun Labs
Human-Relevant Testing.
Without Harming Animals.
Lebrun Labs has spent a decade building, validating, and patenting safety testing methods that achieve high accuracy and human relevancy and backed by $4.5M+ in NIH funding. We are now seeking the right partners to scale this technology globally.
$4.5M+
NIH Grant Funding
Awarded since 2015
5
Issued U.S. Patents
Active, 2018–2026
Live
Validated, Shelf-Stable Kits
Commercially ready, kits ship today
$2B+
Market Addressable
Global safety testing market
Market Context
Why the Timing Is Right
Regulators Are Mandating Human-Relevant Science
The EU has banned cosmetics animal testing (EU Cosmetics Regulation 1223/2009). The U.S. EPA is phasing out mammalian toxicity studies (EPA, 2019). The FDA Modernization Act 2.0 (signed December 2022) explicitly requires consideration of human-relevant alternatives. Regulators worldwide are converging on the same conclusion: animal data is a poor proxy for human outcomes.
Human-Relevant Methods Outperform Animal Tests
OptiSafe™, IVD EIT™, and DermaSafe™ are validated, shelf-stable, nonanimal test kits and contract services, commercially ready today. Human-relevant methods are not just more ethical; they are more scientifically rigorous and reproducible than legacy animal tests.
De-Risked by $4.5M in NIH Funding
Over $4.5M in competitive NIH SBIR grants have funded the development and independent validation of Lebrun Labs human-relevant methods. Government-funded peer review is the strongest possible third-party endorsement of scientific merit and commercial readiness.
Intellectual Property Portfolio
Human-Relevant IP You Can Acquire or License
Five issued U.S. patents covering human-biology-based test methods, validated, commercially deployed, and accepted under OECD regulatory frameworks. Each method is designed around human biochemistry, not animal surrogates.
OptiSafe™
Human-Relevant Ocular Irritation Test, OECD 496
Models the biochemistry of the human eye, not rabbit ocular tissue. 92% accuracy for GHS classification, 88% for EPA. Outperforms the Draize rabbit eye test by using human-relevant tear factors.
IVD EIT™
Human Tear Chemistry-Based Eye Irritation Test
The only nonanimal ocular test that incorporates patented human tear antioxidant chemistry (US12115147B2, US12521367B2), reducing false-positive rates from ~40% to ~20% (Lebrun et al., 2024; US12115147B2). Animal tests cannot replicate the protective antioxidant capacity of human tears; IVD EIT™ does.
DermaSafe SCT™
Human-Relevant In Chemico Skin Corrosion Test
Cell-free platform (US12559784B2) measuring enzyme activity reduction, a human-relevant biochemical endpoint. Extensible beyond skin to neurotoxicity, pulmonary, hepatic, and cardiac endpoints, all grounded in human biochemistry rather than animal surrogates.
Emergency Eyewash
Human Tear Chemistry-Inspired Ocular Protection (US12648892B2)
Formulated around the antioxidant chemistry of human tears. Clinically superior to standard saline eye wash protocols because it addresses the actual biochemical mechanism of chemical ocular injury in humans, not a generic dilution approach.
Product Commercialization
Emergency Eyewash, Ascorbate Buffer
A portable, ascorbate-based emergency eyewash that outperforms water irrigation, backed by NEI CounterACT funding, a blinded human clinical trial, and a pending international patent portfolio.
Growth Opportunity
Patent Pipeline
Beyond the five issued patents, Lebrun Labs has additional patent applications pending, extending the human-relevant in chemico platform into new toxicity endpoints with no currently accepted nonanimal alternatives.
In Chemico Neurotoxicity Test
Extension of the DermaSafe SCT™ enzyme-activity platform to acute neurotoxicity endpoints. Applies the same human-relevant in chemico methodology to a toxicity category with no currently accepted nonanimal alternative, a significant regulatory and commercial gap.
In Chemico Pulmonary Toxicity Test
Applies the patented in chemico platform (US12559784B2) to pulmonary toxicity screening. Addresses growing demand from inhalation safety testing for industrial chemicals, consumer aerosols, and pharmaceutical inhalation products.
Expanded Ocular Irritation Classification
Next-generation refinement of the IVD EIT™ system incorporating additional human tear biochemistry markers to further reduce false-positive and false-negative rates across a broader range of chemical classes and formulation types.
Interested in licensing or working with our technology?
Reach out and tell us what you have in mind, we're open to a range of arrangements.
How to Engage
Three Paths to Partnership
Equity Investment
Scale a Proven, Human-Relevant Testing Platform
Lebrun Labs has built the only commercially deployed, OECD-accepted nonanimal safety testing platform that models human biochemistry, not animal physiology. De-risked through $4.5M in NIH funding, independent NICEATM validation, and OECD regulatory acceptance, the platform is ready to scale. An equity investment would accelerate manufacturing capacity, grow the contract research team, and expand OptiSafe™, DermaSafe SCT™, and IVD EIT™ into new global markets.
Key Highlights
- Validated, human-relevant platforms that outperform legacy animal methods across ocular, dermal, and cytotoxicity endpoints
- Revenue-generating today: contract research and test kit sales
- Five issued patents covering human-biology-based methods and formulations
- Patent pipeline extending the platform to neurotoxicity, pulmonary, and hepatic endpoints
- Regulatory tailwinds: EU ban, EPA phase-out, FDA Modernization Act 2.0
- Scalable kit-based model with high gross margins
Strategic Acquisition / Buyout
Acquire the Leader in Human-Relevant Safety Testing
Lebrun Labs represents a rare opportunity to acquire a complete, commercially validated human-relevant safety testing platform. The transaction includes five issued U.S. patents, OECD-accepted methods, established regulatory relationships, and a proven scientific team. Valuation is commensurate with the depth of the IP portfolio, the regulatory acceptance already in place, and the scale of the addressable market. Serious inquiries are handled confidentially and directly with leadership.
Key Highlights
- Turnkey platform: IP, validated methods, team, and customer relationships transfer together
- Immediate revenue from active contract research and kit sales
- Defensible IP moat as the only OECD-accepted human tear chemistry-based ocular test
- Patent pipeline extends the platform to additional unlicensed endpoints at no incremental R&D cost
- Aligned with ESG mandates, animal welfare commitments, and global regulatory direction
- Valuation discussions are conducted under NDA, contact us to begin
B2B Strategic Partnership
Work With Us, Tell Us What You Have in Mind
We are open to a wide range of B2B arrangements with companies, distributors, CROs, and research organizations who see value in human-relevant safety testing. If you have an idea for how we might work together, we want to hear it, no predefined structure required.
Investor Inquiry
Start a Confidential Conversation
Whether you're exploring an equity stake, a full acquisition, or a strategic B2B arrangement, complete the form below and we'll be in touch. All discussions are subject to NDA upon request.
Lebrun Labs · Anaheim, CA · [email protected]
References
- 1. [LL] Lebrun S. (2018). U.S. Patent No. US10041922B2: Biochemistry Based Ocular Toxicity Assay (OptiSafe™). USPTO. Granted August 7, 2018. Independently validated by NICEATM: 92% accuracy (EPA), 88% accuracy (GHS). https://patents.google.com/patent/US10041922B2/en
- 2. NICEATM / NTP. (2020). Validation Study Report: OptiSafe™ Ocular Irritation Test. National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, National Institute of Environmental Health Sciences. https://ntp.niehs.nih.gov/whatwestudy/niceatm/test-method-evaluations/ocular-irritation
- 3. [LL] Lebrun S, Nguyen L, Ho C. (2024). Evaluation of a new in chemico skin corrosion test. Toxicology in Vitro 101:105940. doi:10.1016/j.tiv.2024.105940
- 4. [LL] Lebrun S, Nguyen L. (2026a). U.S. Patent No. US12559784B2: In Chemico Test for Toxicity. USPTO. Granted February 24, 2026. https://patents.google.com/patent/US12559784B2/en
- 5. [LL] Lebrun S, Nguyen L. (2026b). U.S. Patent No. US12648892B2: Emergency Eye Wash. USPTO. Granted June 9, 2026. https://patents.google.com/patent/US12648892B2/en
- 6. [LL] Lebrun S, Chan R, Chavez S. (2024c). U.S. Patent No. US12115147B2: Formulations and Methods Related to Eye Irritation. USPTO. Granted October 15, 2024. False-positive rate reduction (~40% → ~20%) reported in patent specification. https://patents.google.com/patent/US12115147B2/en
- 7. European Commission. (2009). Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products (EU Cosmetics Regulation). Official Journal of the European Union. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32009R1223
- 8. U.S. EPA. (2019). Strategic Plan to Promote the Development and Implementation of Alternative Test Methods Within the TSCA Program. U.S. Environmental Protection Agency. https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/strategic-plan-promote-development-and-implementation
- 9. U.S. Congress. (2022). FDA Modernization Act 2.0 (Pub. L. 117-328, Division FF, Title III). Signed December 29, 2022. Amends the Federal Food, Drug, and Cosmetic Act to allow alternatives to animal testing for drug approval. https://www.congress.gov/bill/117th-congress/senate-bill/5002
[LL] = Lebrun Labs LLC patent or publication. All accuracy and validation figures are sourced from the cited patents and independent NICEATM validation reports.